BioMarin's Q3 Results and Business Update Might Change The Case For Investing In BMRN

• BioMarin Pharmaceutical announced its third quarter 2025 financial results and provided a business update in a conference call hosted by CEO Alexander Hardy on October 27, 2025, following the market close.
• This quarterly report comes amid high analyst expectations for continued revenue growth and positive business momentum, with most estimates reaffirmed in recent weeks.
• We'll look at how analyst optimism about BioMarin's sustained revenue growth and business outlook shapes the company's updated investment narrative.

Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

BioMarin Pharmaceutical Investment Narrative Recap

To be a shareholder in BioMarin Pharmaceutical, you need to believe in the long-term expansion of its rare disease treatments and the ability to deliver meaningful revenue growth from its pipeline. The recent Q3 2025 earnings announcement is not expected to materially shift the most important short-term catalyst, the international rollout and market penetration of VOXZOGO, or the primary risk, which remains competitive threats to its leading products and potential pricing pressures. Among recent announcements, new clinical data on VOXZOGO presented in September reinforce the company’s case for continued growth in achondroplasia treatment, adding to the momentum seen as BioMarin expands its reach in rare disease markets. These scientific advances are closely linked to top-line growth drivers, making the consistency of such data critical as competition intensifies and pricing scrutiny rises across global markets. By contrast, hidden beneath the surface is the risk that stronger competition or changing reimbursement trends could suddenly...

Read the full narrative on BioMarin Pharmaceutical (it's free!)

BioMarin Pharmaceutical's narrative projects $3.8 billion in revenue and $1.1 billion in earnings by 2028. This requires 7.6% yearly revenue growth and a $442.8 million increase in earnings from the current $657.2 million.

Uncover how BioMarin Pharmaceutical's forecasts yield a $94.80 fair value, a 74% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community placed BioMarin’s fair value between US$83.91 and US$177.97, showing wide differences even among individual forecasts. With competition and payer pressures looming as key risks, see how different perspectives weigh potential headwinds and opportunities for BioMarin’s future performance.

Explore 4 other fair value estimates on BioMarin Pharmaceutical - why the stock might be worth just $83.91!

Build Your Own BioMarin Pharmaceutical Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your BioMarin Pharmaceutical research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free BioMarin Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioMarin Pharmaceutical's overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Outshine the giants: these 27 early-stage AI stocks could fund your retirement.
• The end of cancer? These 27 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com